<?xml version="1.0" encoding="UTF-8"?><bill xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm uslm-2.0.10.xsd" xml:lang="en"><meta><dc:title>116 H. R. 2009 IH: To amend titles XVIII and XIX of the Social Security Act to provide equal coverage of in vitro 			 specific IgE tests and percutaneous tests for allergies under the Medicare 			 and Medicaid programs, and for other purposes.</dc:title><dc:type>House Bill</dc:type><dc:creator>U.S. House of Representatives</dc:creator><congress>116</congress><session>1</session><docNumber>2009</docNumber><docStage>IH</docStage><citableAs>116hr2009ih</citableAs><citableAs>116 H. R. 2009 IH</citableAs><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><processedBy>Xcential BillDTD to USLM Converter v20210601</processedBy><processedDate>2021-11-19</processedDate><publicPrivate>public</publicPrivate></meta><preface><dc:type>H. R. </dc:type><docNumber>2009</docNumber><congress value="116">116th CONGRESS</congress><session value="1">AT THE FIRST SESSION</session></preface><main id="H709ECD49732D45A89DB8797CF17DA82E"><longTitle><docTitle>A BILL</docTitle><officialTitle>To amend titles XVIII and XIX of the Social Security Act to provide equal coverage of in vitro 			 specific IgE tests and percutaneous tests for allergies under the Medicare 			 and Medicaid programs, and for other purposes.</officialTitle></longTitle><enactingFormula>Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,</enactingFormula><section identifier="/s1" id="HBE2223CD8F8545BFB56D257DA59C0C81" class="bill-dtd-OLC"><num value="1">SECTION 1.</num><heading> SHORT TITLE.</heading><content class="indent0">This Act may be cited as the “<shortTitle>Removing Barriers to Allergy Diagnostic Testing Act of 2019</shortTitle>”.</content></section><section identifier="/s2" id="H2E58039B2E334CF9BAD418FBCF6DB088" class="bill-dtd-OLC"><num value="2">SEC. 2.</num><heading> FINDINGS.</heading><chapeau>Congress finds the following:</chapeau><paragraph identifier="/s2/1" id="HCA908768A8BC4D83A636628B82CF43BD" class="bill-dtd-OLC"><num value="1">(1)</num><content> Allergies, when not properly diagnosed, cannot be effectively treated.</content></paragraph><paragraph identifier="/s2/2" id="HAD966A4EFCDA421282C1A85FEA5C2D3D" class="bill-dtd-OLC"><num value="2">(2)</num><content> Allergies to food, inhaled particles, or other sources can cause debilitating and, in some cases, fatal reactions.</content></paragraph><paragraph identifier="/s2/3" id="H0211839E487A4AD29E0E91FA43424A5A" class="bill-dtd-OLC"><num value="3">(3)</num><content> Allergies can substantially compound other illnesses, including asthma, emphysema, and adult obstructive pulmonary diseases, leading to social and economic costs for families and our Nation’s health care system.</content></paragraph><paragraph identifier="/s2/4" id="HB1F39D8DA20D4C68ABBCEC9D38A186A4" class="bill-dtd-OLC"><num value="4">(4)</num><content> According to clinical guidelines from the National Institutes of Health and recommendations from peer-reviewed literature, in vitro specific IgE tests and percutaneous tests are considered equivalent as confirmatory tests in terms of their sensitivity and accuracy.</content></paragraph><paragraph identifier="/s2/5" id="H24ACF440EE3247A08C342EE549EB7359" class="bill-dtd-OLC"><num value="5">(5)</num><content> Despite these recommendations, some current Medicare local coverage determinations and Medicaid coverage policies deny equal access to in vitro specific IgE tests and percutaneous tests.</content></paragraph><paragraph identifier="/s2/6" id="H0410D80EB05346BB81EE31BD3A9C0298" class="bill-dtd-OLC"><num value="6">(6)</num><content> In vitro specific IgE tests and percutaneous tests must be equally accessible for clinicians and patients to improve health outcomes, reduce system costs, and reduce current health care disparities caused by the lack of equal coverage.</content></paragraph></section><section identifier="/s3" id="HA3F5AB96E8D74892ACC90C1EDF6E7527" class="bill-dtd-OLC"><num value="3">SEC. 3.</num><heading> MEDICAID COVERAGE FOR ALLERGY DIAGNOSTIC TESTING SERVICES.</heading><subsection identifier="/s3/a" id="H8BC1665AE76444C48FA5BCDF6FC3ADF9" class="bill-dtd-OLC"><num value="a">(a)</num><heading> In General.—</heading><chapeau>Title XIX of the Social Security Act (<ref href="/us/usc/42/1396">42 U.S.C. 1396</ref> et seq.) is amended—</chapeau><paragraph identifier="/s3/a/1" id="HAFA07A8DF4B243F48F7A1C19D35BDFAD" class="bill-dtd-OLC"><num value="1">(1)</num><chapeau> in section 1902(a)—</chapeau><subparagraph identifier="/s3/a/1/A" id="H35772BC65DED4021A12E2575200EC11B" class="bill-dtd-OLC"><num value="A">(A)</num><content> in paragraph (85), by striking “<quotedText>and</quotedText>” at the end;</content></subparagraph><subparagraph identifier="/s3/a/1/B" id="HDB74495491CD4A84A6DCEFDEA743BA4C" class="bill-dtd-OLC"><num value="B">(B)</num><content> in paragraph (86), by striking the period at the end and inserting “<quotedText>; and</quotedText>”; and</content></subparagraph><subparagraph identifier="/s3/a/1/C" id="HB0148E49CDEA4C76B53DAA23C1393272" class="bill-dtd-OLC"><num value="C">(C)</num><content> by inserting after paragraph (86) the following new paragraph:<quotedContent id="H5DF0880D87D847FC838072500A1E80E7"><paragraph identifier="/s3/a/1/C/qB/87" id="H9285A8F2D00A4DB79ACFE48601BEB25A" class="bill-dtd-OLC"><num value="87">“(87)</num><chapeau> provide, with respect to the provision of allergy diagnostic testing services (as defined in section 1905(ee)) under the State plan, for equality in the treatment of in vitro specific IgE tests and percutaneous tests with respect to—</chapeau><subparagraph identifier="/s3/a/1/C/qB/87/A" id="H8D0BFFE103774F009D16F2E7E3EFF652" class="bill-dtd-OLC"><num value="A">“(A)</num><content> any medical necessity or other coverage requirements established for such in vitro specific IgE and percutaneous tests;</content></subparagraph><subparagraph identifier="/s3/a/1/C/qB/87/B" id="H7341665F674149A08ED269331211816A" class="bill-dtd-OLC"><num value="B">“(B)</num><content> any frequency limits established for such tests; and</content></subparagraph><subparagraph identifier="/s3/a/1/C/qB/87/C" id="H17DA69E30F9F498C8041B5DAA7806D09" class="bill-dtd-OLC"><num value="C">“(C)</num><content> any allergen unit limits established for such tests.”</content></subparagraph></paragraph></quotedContent>; and</content></subparagraph></paragraph><paragraph identifier="/s3/a/2" id="HD720BF6D61444959BE9A466ACB750184" class="bill-dtd-OLC"><num value="2">(2)</num><chapeau> in section 1905—</chapeau><subparagraph identifier="/s3/a/2/A" id="HBC8322CCF8A24C49BBC136831FCDAD76" class="bill-dtd-OLC"><num value="A">(A)</num><chapeau> in subsection (r)—</chapeau><clause identifier="/s3/a/2/A/i" id="H3C492323D8A54C0A938B266584D469B1" class="bill-dtd-OLC"><num value="i">(i)</num><content> by redesignating paragraph (5) as paragraph (6); and</content></clause><clause identifier="/s3/a/2/A/ii" id="HEC70F9902960447DB6D327F1B1AFDF0C" class="bill-dtd-OLC"><num value="ii">(ii)</num><content> by inserting after paragraph (4) the following new paragraph:<quotedContent id="H7CB13D26B80C4637829DA9A78F15AB4F"><paragraph identifier="/s3/a/2/A/ii/qB/5" id="H95A7F877F54D40999902BA0CDE7D1991" class="bill-dtd-OLC"><num value="5">“(5)</num><content> Allergy diagnostic testing services (as defined in subsection (ff)).”</content></paragraph></quotedContent>; and</content></clause></subparagraph><subparagraph identifier="/s3/a/2/B" id="H985F324FB04B4477AF9C99D096ED3739" class="bill-dtd-OLC"><num value="B">(B)</num><content> by adding at the end the following new subsection:<quotedContent id="HB06540F44E71423BB5A657A75E20B45A"><subsection identifier="/s3/a/2/B/qB/ff" id="HCDCB06D0DF944C139C72C54389C59D06" class="bill-dtd-OLC" role="definitions"><num value="ff">“(ff)</num><heading> Allergy Diagnostic Testing Services Defined.—</heading><chapeau>The term ‘<term>allergy diagnostic testing services</term>’ means in vitro specific IgE tests and percutaneous tests that—</chapeau><paragraph identifier="/s3/a/2/B/qB/ff/1" id="H996EA723083D41CEB1334348327D7016" class="bill-dtd-OLC"><num value="1">“(1)</num><content> have been cleared under section 501(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and</content></paragraph><paragraph identifier="/s3/a/2/B/qB/ff/2" id="H10D564DB28F54792AD7689BE3D2417E9" class="bill-dtd-OLC"><num value="2">“(2)</num><content> are provided to individuals for the purpose of evaluating immunologic response to certain antigens.”</content></paragraph></subsection></quotedContent>.</content></subparagraph></paragraph></subsection><subsection identifier="/s3/b" id="H19F3B0D5B91040AABD680E9F7D424F4A" class="bill-dtd-OLC"><num value="b">(b)</num><heading> Effective Date.—</heading><paragraph identifier="/s3/b/1" id="H7B03C24EE5164762858024EAAFA498C6" class="bill-dtd-OLC"><num value="1">(1)</num><heading> In general.—</heading><content>Subject to paragraph (2), the amendments made by this section shall apply with respect to items and services provided on or after January 1, 2021.</content></paragraph><paragraph identifier="/s3/b/2" id="H801A5DAE0D254CE29E64EDF35769CE3E" class="bill-dtd-OLC"><num value="2">(2)</num><heading> Exception for State legislation.—</heading><content>In the case of a State plan under title XIX of the Social Security Act (<ref href="/us/usc/42/1396">42 U.S.C. 1396</ref> et seq.) that the Secretary of Health and Human Services determines requires State legislation in order for the respective plan to meet any requirement imposed by amendments made by this section, the respective plan shall not be regarded as failing to comply with the requirements of such title solely on the basis of its failure to meet such an additional requirement before the first day of the first calendar quarter beginning after the close of the first regular session of the State legislature that begins after the date of the enactment of this Act. For purposes of the previous sentence, in the case of a State that has a 2-year legislative session, each year of the session shall be considered to be a separate regular session of the State legislature.</content></paragraph></subsection></section><section identifier="/s4" id="H1E5CDA4503084C6C9603363BB36BBE2A" class="bill-dtd-OLC"><num value="4">SEC. 4.</num><heading> MEDICARE COVERAGE FOR ALLERGY DIAGNOSTIC TESTING SERVICES.</heading><subsection identifier="/s4/a" id="H9C90CAA5927D425E85AF739191E72C76" class="bill-dtd-OLC"><num value="a">(a)</num><heading> Coverage.—</heading><chapeau>Section 1861 of the Social Security Act (<ref href="/us/usc/42/1395x">42 U.S.C. 1395x</ref>) is amended—</chapeau><paragraph identifier="/s4/a/1" id="H58D8BF945B74448192F069923DF71F27" class="bill-dtd-OLC"><num value="1">(1)</num><chapeau> in subsection (s)(2)—</chapeau><subparagraph identifier="/s4/a/1/A" id="H3C6B691D58C6407EA558AFEE6F6C0CAC" class="bill-dtd-OLC"><num value="A">(A)</num><content> in subparagraph (GG), by striking “<quotedText>and</quotedText>” at the end;</content></subparagraph><subparagraph identifier="/s4/a/1/B" id="HCA6BCA6A28B04CF682AD3D08925D5144" class="bill-dtd-OLC"><num value="B">(B)</num><content> in subparagraph (HH), by striking the period at the end and inserting “<quotedText>; and</quotedText>”; and</content></subparagraph><subparagraph identifier="/s4/a/1/C" id="H59F90AA31BEF4003AB5C60081D9A1BF7" class="bill-dtd-OLC"><num value="C">(C)</num><content> by adding at the end the following new subparagraph:<quotedContent id="H7C6693A145D846DBB942A15437975AAC"><subparagraph identifier="/s4/a/1/C/qB/II" id="H1948F0D4353144F4A7FBEEF972B34569" class="bill-dtd-OLC"><num value="II">“(II)</num><content> allergy diagnostic testing services (as defined in subsection (kkk));”</content></subparagraph></quotedContent>; and</content></subparagraph></paragraph><paragraph identifier="/s4/a/2" id="H53A3248350544053BBD2A2D75046A3A5" class="bill-dtd-OLC"><num value="2">(2)</num><content> by adding at the end the following new subsection:<quotedContent id="H092A6FF25CD847F18E10872B36F65F89"><subsection identifier="/s4/a/2/qB/kkk" id="H8B015183DB5947D18C5CE8C4952668FA" class="bill-dtd-OLC"><num value="kkk">“(kkk)</num><heading> Allergy Diagnostic Testing Services.—</heading><paragraph identifier="/s4/a/2/qB/kkk/1" id="HBB6A4BA9447048418686775A2ABA32A2" class="bill-dtd-OLC" role="definitions"><num value="1">“(1)</num><heading> In general.—</heading><chapeau>The term ‘<term>allergy diagnostic testing services</term>’ means in vitro specific IgE tests and percutaneous tests—</chapeau><subparagraph identifier="/s4/a/2/qB/kkk/1/A" id="H7846C182915C4D409000C6E67287EB7E" class="bill-dtd-OLC"><num value="A">“(A)</num><content> that have been cleared under section 501(k), classified under section 513(f)(2), or approved under section 515 of the Federal Food, Drug, and Cosmetic Act; and</content></subparagraph><subparagraph identifier="/s4/a/2/qB/kkk/1/B" id="H5DC35C6A360F4116B148BF07BA041092" class="bill-dtd-OLC"><num value="B">“(B)</num><content> which are furnished to individuals for the purpose of evaluating immunologic response to certain antigens, as determined appropriate by the practitioner ordering such test.</content></subparagraph></paragraph><paragraph identifier="/s4/a/2/qB/kkk/2" id="HF797456D167B46DEA2160624EAE4080A" class="bill-dtd-OLC"><num value="2">“(2)</num><heading> Equal access to testing methods.—</heading><chapeau>The Secretary shall ensure equality in the treatment of in vitro specific IgE tests and percutaneous tests described in paragraph (1) with respect to—</chapeau><subparagraph identifier="/s4/a/2/qB/kkk/2/A" id="HB2EBF573508F466289D792F7DECF23FE" class="bill-dtd-OLC"><num value="A">“(A)</num><content> any medical necessity or other coverage requirements established for such in vitro specific IgE and percutaneous tests;</content></subparagraph><subparagraph identifier="/s4/a/2/qB/kkk/2/B" id="H469D079D47174919AE96F90AEE63FF33" class="bill-dtd-OLC"><num value="B">“(B)</num><content> any frequency limits established for such tests; and</content></subparagraph><subparagraph identifier="/s4/a/2/qB/kkk/2/C" id="H469DDB8DDD3C4FBEA7A8E9E7411E4BAF" class="bill-dtd-OLC"><num value="C">“(C)</num><content> any allergen unit limits established for a year for such tests.”</content></subparagraph></paragraph></subsection></quotedContent>.</content></paragraph></subsection><subsection identifier="/s4/b" id="H4A440966EEC34B74BD61BAC654FF5584" class="bill-dtd-OLC"><num value="b">(b)</num><heading> Payment.—</heading><content>Section 1834 of the Social Security Act (<ref href="/us/usc/42/1395m">42 U.S.C. 1395m</ref>) is amended by adding at the end the following new subsection:<quotedContent id="H6DF5F8A95C9749BD9E5928DD7E6EA2EE"><subsection identifier="/s4/b/qB/x" id="HFE0712D1EA574A41BCEAE5396689C40B" class="bill-dtd-OLC"><num value="x">“(x)</num><heading> Allergy Diagnostic Testing Services.—</heading><chapeau>For purposes of payment only, in the case of allergy diagnostic testing services (as defined in section 1861(jjj))—</chapeau><paragraph identifier="/s4/b/qB/x/1" id="HF81D9D8EA9E9421BADBE28E5B8EDA478" class="bill-dtd-OLC"><num value="1">“(1)</num><content> in vitro specific IgE tests shall be treated as clinical diagnostic laboratory tests; and</content></paragraph><paragraph identifier="/s4/b/qB/x/2" id="HABE6217174F048EBA416C1C45197E38B" class="bill-dtd-OLC"><num value="2">“(2)</num><content> percutaneous tests shall be treated as physicians’ services.”</content></paragraph></subsection></quotedContent>.</content></subsection><subsection identifier="/s4/c" id="H3BD13973EA9F4B1AA4A5CEA6DCEA34BA" class="bill-dtd-OLC"><num value="c">(c)</num><heading> Effective Date.—</heading><content>The amendments made by this section shall apply with respect to items and services furnished on or after January 1, 2021.</content></subsection></section></main></bill>